Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549652 · ClinicalTrials.gov registry record · NA
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
A NA study of Opioid Withdrawal and Physical Dependence, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 133
- Enrollment target
- 1
- Study location
NCT01549652 is a NA study of Opioid Withdrawal and Physical Dependence that has completed, run by Stanford University. The registered enrollment target is 133 participants, above the 110-participant average among 9 other Opioid Withdrawal trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01549652, a NA study of Opioid Withdrawal and Physical Dependence, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 133 participants
- Enrollment target
- 1
- Study location
Study Summary
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects (such as agitation and nausea) if opioid medications are suddenly stopped. This study aims to test the use of the drug ondansetron to reduce the symptoms associated with opioid withdrawal and to prevent the progression of opioid physical dependence, thereby allowing future investigators to better test the role of physical dependence in the development of addiction and also possibly improving acceptance of abstinence-based programs for addiction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ondansetron
- DRUG Morphine
- DRUG Naloxone 0.4 mg/70 kg
- DRUG Naloxone 0.8 mg/70 kg
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01549652
The ClinicalTrials.gov registry entry for NCT01549652 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 9 other Opioid Withdrawal trials with a reported enrollment target (21% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid Withdrawal appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01549652 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01549652 about?
NCT01549652 is a clinical study titled "5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence". Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects (such as agitation and nausea) if opioid medications are suddenly stopped. This study aims to test the use of the drug ondansetron to reduce the symptoms...
What is the current status of trial NCT01549652?
This trial is currently completed. It is a NA study. The enrollment target is 133 participants. The study started on 2011-04. Estimated completion is 2016-10.
What conditions does trial NCT01549652 study?
This clinical trial studies the following conditions: Opioid Withdrawal, Physical Dependence.
What interventions are being tested in trial NCT01549652?
The interventions under investigation include: Placebo (DRUG), Ondansetron (DRUG), Morphine (DRUG), Naloxone 0.4 mg/70 kg (DRUG), Naloxone 0.8 mg/70 kg (DRUG).
Who is sponsoring clinical trial NCT01549652?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01549652 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Withdrawal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
RECRUITING · NA
-
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
COMPLETED · NA
-
ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain
RECRUITING · Phase 1
-
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
RECRUITING
-
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
RECRUITING · Phase 2
-
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.